Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers

NCT01859182 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01859182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01859182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2013
Completion date
May 31, 2013
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gallbladder, adenocarcinoma with squamous metaplasia of the gallbladder, adult primary cholangiocellular carcinoma, advanced adult primary liver cancer, cholangiocarcinoma of the extrahepatic bile duct, localized unresectable adult primary liver cancer, metastatic extrahepatic bile duct cancer, recurrent adult primary liver cancer, recurrent extrahepatic bile duct cancer, stage ii gallbladder cancer, stage iiia gallbladder cancer, stage iiib gallbladder cancer, stage iva gallbladder cancer, stage ivb gallbladder cancer, unresectable extrahepatic bile duct cancer